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SUMMARY
The usefulness of several different methods for detecting immune complex formation and
complement activation in the circulation were applied to samples from patients receiving intravenous
Streptokinase therapy for myocardial infarction. Streptokinase is a foreign antigen and can cause
immune reactions. We collected samples from 13 patients, before Streptokinase administration
(baseline), at the end of infusion (I h), 12 h later and on day 7. We measured IgG containing immune
complexes (IgG-IC), free C3d and antibodies to Streptokinase by ELISA, and CRI, C3d and C4d on
erythrocytes by flow cytometric assay. Antibodies to Streptokinase are common, as all but two of the
patients had measurable antibody levels. During Streptokinase treatment there was a drop in
antibody levels, most prominent in those patients who had high baseline levels. At the same time
increased levels of free C3d and erythrocyte-bound C3d were observed. After 12 h free C3d was
usually back to baseline level, but C3d on erythrocytes was still raised. These data indicate the
formation of Streptokinase immune complexes in patients with high Streptokinase antibody levels,
and show that these complexes are cleared rapidly from the circulation, leaving more persistent signs
of complement activation. We conclude that free C3d is a good indicator of ongoing complement
activation, whereas C3d on erythrocytes indicates that complement activation has recently taken
place.
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INTRODUCTION activity in SLE and other diseases. Amongst these are measure-
Immune complex formation and subsequent complement acti- ments of complement activation products in serum [4-7],
vation play a crucial role in the pathogenesis of several diseases assessment of C3 metabolic turnover [8] and changes in the
such as systemic lupus erythematosus (SLE) and are also of amount of complement receptor CRI (CD35) on erythrocytes
> . [~~~~9-11]. These measurements seem to correlate better withimportance in the disease mechanism of many other illnesses [ . .
like rheumatoid arthritis (RA), chronic infections, AIDS and disease activity than the more classical tests.
drug reactions. Several serological parameters are helpful in We have established assays for measuring IC formation and
diagnosing and classifying immune complex-mediated diseases. complement activation products in the circulation. Amongst
Measurement of these parameters has been used extensively to these assays are flow cytometric measurements of the comple-
evaluate disease activity and severity. Most commonly used are ment fragments C3d and C4d and their receptor (CR1) on the
measurements of autoantibody titre and reactivity pattern (e.g. surface of erythrocytes, and ELISA assays for measuring free
anti-nuclear antibodies and anti-DNA antibodies), quantitative C3d and C3d containing IC in plasma. We wanted to see how
or functional measurements of complements (e.g. serum C3, well these methods could detect IC formation and complement
serum C4 and CH-io) and measurement of serum immune activation compared with a traditional assay, C3 rocket electro-
complexes (IC). Although these measurements often correlate phoresis, widely used by clinicians to evaluate disease severity.
with disease activity, there is wide individual variation and quite Before applying these methods on selected patient groups we
often these laboratory values do no more than support the established a simple model in which we could be sure that
* . ~~~~~~~~~~~~~complementactivation would take place and at what time itclinical evaluation [1-3]. Over the last few years several reports
have described the use of new methods for assessing disease hapeed Thrfrw' netgtdainsrciigSrp
tokinase as treatment for myocardial infarction.
Correspondence: Asbjorn Sigfusson, Department of Immunology, Streptokinase (SK) is a 47-kD protein produced by /3-
The National University Hospital, Landspitalinn, 101 Reykjavik, haemolytic streptococci group C. Since streptococcal infections
Iceland. are not rare, antibodies to SK are common [12]. For the last
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decade SK has been widely used in patients with myocardial temperature. AP-conjugated rabbit anti-human C3d (A063,
infarction or peripheral artery occlusion because ofits thrombo- AP-conjugated at our laboratory) diluted 1: 500 was incubated
lytic properties. It is most commonly administered intraven- overnight at room temperature. NPP was used as the developing
ously in large quantities over a short period of time. When reagent as described before. Zymosan-activated serum (in which
myocardial infarction patients who have antibodies to SK C3 had been cleaved to generate C3d) was used as standard and
receive 600 mg of SK intravenously over 1 h, IC formation and the 1:200 dilution was given 500 AU.
subsequent complement activation are likely to take place,
making these patients ideal for evaluating our assays. IgG-IC in plasma
IgG isotype-specific IC were measured by an ELISA assay.
PATIENTS AND METHODS ELISA plates (Immulon 1, Dynatech) were coated overnight at
Patients 40C with Fab2 rabbit anti-human C3d (A063, Dako), diluted
Thirteen patients who received intravenous SK for myocardial 1:500 (2-5 pg/ml) in bicarbonate buffer. Plasma samples, diluted
infarction were studied. Both EDTA blood and whole blood 1: 50, and standard in two-fold serial dilutions starting at 1: 40,
were collected before treatment (baseline value), at the end of were incubated for 5 h at room temperature. Then AP-
the 1-h SK infusion 12 h later and 7 days after the SK conjugated rabbit anti-human IgG (D336, Dako), diluted
'nan aa sera were aliquoted and stored at 1: 500, was incubated overnight at room temperature. Develop-
administration Plasmaed, and erythrocytes wereanalysedwithin ing was done as described before. The standard was made by
-700C until measured, but ana wit icbtn etageae omlhmnsrm(H)wt
48 h of sampling. Four patients with myocardial infarct who did freshaNHS gatedCnorm2 l hich enured c l t
not receive SK treatment were included for comparison. fehNSa 7Cfr2hwihesrdcmlmn
opsonization of the aggregate. A dilution of 1:40 was given 100
Streptokinase antibodies AU.
Antibodies to SK were measured by an ELISA assay. ELISA
plates (Maxisorp, Nunc, Roskilde, Denmark) were coated Erythrocyte-bound CRI, C3d and C4d
overnight at 40C with 2-5 Mg/ml of Streptokinase (Strepase, CR1, C3d and C4d on erythrocytes were measured by a flow
Behring, Marburg, Germany), diluted in bicarbonate buffer (pH cytometric assay as previously described [ 14]. Erythrocytes were
9 6). Serum samples at 1: 100 dilution and standard in two-fold washed three times in PBS with 1% fetal calf serum (PBS/FCS)
serial dilutions starting at 1: 100 were incubated for 5 h at room and a 1% solution made by adding PBS/FCS to packed
temperature. Then alkaline phosphatase (AP)-conjugated rab- erythrocytes. Ten microlitres of 1% erythrocytes were mixed
bit anti-human IgG (D336, Dako), diluted 1:2000 was incu- with 50 p1 of either mouse anti-human CR1 (M710, Dako), 55
bated overnight at room temperature. The substrate, para- pg/ml, rat anti-human C3d (clone 3, kindly provided by
nitrophenylphosphate (NPP; Sigma, St Louis, MO), 5 mg/ml in Professor Peter Lachmann, Cambridge, UK), ascites diluted
10% diethanolamine buffer (pH 9 8), was then added and the 1:10000 or mouse anti-human C4d (clone T2C5, kindly
optical density of the developing colour measured at 405 nm in provided by Dr Gordon Ross, University of North Carolina,
an ELISA reader (Titertech Multiscan, Flow Labs). The NC), 1 0 pg/ml, and incubated on ice for 45 min. Erythrocytes
standard was made from serum obtained from a person were then washed twice, mixed with 30 p1 of FITC-conjugated
receiving intradermal injections ofSK. The 1: 100 dilution of the rabbit anti-mouse 1: 50, or rabbit anti-rat 1: 20, and incubated
standard was given 100 arbitrary units (AU) and a standard on ice for 30 min. Erythrocytes were washed again and
curve established, from which AU units for the samples were resuspended in 800 pi of 0-5% paraformaldehyde. Two thou-
read. sand erythrocytes were analysed in a flow cytometer (FACScan,
Becton Dickinson, Stockholm, Sweden) using FACScan pro-
Serum C3 gram. Results were expressed as median fluorescence (MFCN).
Serum C3 was measured by a rocket immunoelectrophoresis.
Samples, diluted 1: 20, and Standard-Human-Serum (Behring)
were run in 1-2% agarose containing 0 5 p1/cm2 rabbit anti- RESULTS
human C3c (A062, Dako, Glostrup, Denmark) for 3 5 h at 10
V/cm. The amount (g/l) of C3 in the samples was read from a Streptokinase antibodies
standard curve made from the Standard-Human-Serum. Figure 1 shows the distribution ofSK antibody levels in samples
from 13 patients receiving SK infusion with patients numbered
Free C3d in plasma in order of decreasing baseline SK antibody levels. Figure 1 also
The method used was a slight modification of a C3d ELISA shows the changes in SK antibody levels during and after the SK
previously reported [13]. ELISA plates (Maxisorp, Nunc) were infusion. The baseline levels did not differ from what we had
coated with rabbit anti-human C3d (A063, Dako), diluted previously found in healthy individuals (data not shown). These
1:1000 in bicarbonate buffer overnight at 40C. The plates were changes followed a similar pattern in all the patients who had
blocked with 1% bovine serum albumin (BSA) in PBS for I h at measurable baseline levels of SK antibodies, where antibody
room temperature. To precipitate IC bound C3d, plasma levels dropped dramatically during SK infusion and stayed low
samples and standard were mixed with equal volume of 22%/, during the next 12 h. By day 7 the antibody levels had risen,
polyethylene glycol (PEG 6000) in borate buffer (pH 8 3) and often enormously. It is interesting that in some patients with
kept on ice for 60 mmn and then centrifuged at 1500 g at 4 TC for very low baseline levels of SK antibodies, the antibody levels
30 min. The supernatants, containing free C3d, were diluted increased many-fold, but in others the rise was not substantial.
1:100 for plasma samples and the standard in two-fold serial The four control patients not receiving SK infusion had
dilutions starting at 1:200, and incubated for 5 h at room intermediate baseline levels of SK antibodies (Table 1).
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>6000 Table 1. Relation between levels of Streptokinase (SK) antibodies and
changes of serum C3, free C3d and erythrocyte-bound C3d during
1500 SK infusion
1000
500 Baseline Changes in complement fragments
,,,200't- " 8 8 " elevels during SK infusion*0 ofSK
oc 160 Patient antibodies Serum C3 Free C3d Erythrocyte-bound
120 number (AU) (gil) (AU) C3d (MFCN)
80 SKlt 148 -0-07 325 65
40 SK2 118 -024 435 51
* 4 T~~~~~~~~~~~ ~ SK3 56 -0-13 354 49
O MrS3r' SK4 34 -010 272 NT
2 3 4 3 7 8 9 10 I 12 13 SK5 21 -013 155 10
Patient number SK6 13 -0-04 0 10
Fig. 1. Changes in Streptokinase (SK) antibody levels during and after SK7 7 0.0 63 NT
SK infusion. The patients are numbered in order of decreased baseline SK8 6 -0 05 21 5
SK antibody levels. *, 0 h; 0, 1 h; U1, 12 h; U, 7 days. SK9 4 0 05 53 -7
SKIO 3 0-06 7 20
SKI 1 2 -0-19 1 1 7
SK12 0 -0-05 52 8
Serum C3, free C3d and C3d on erythrocytes SK13 0 0.0 7 0
Table I shows the relation between baseline levels of SK CIt 24 NT - I -3
antibodies and changes in C3, free C3d and erythrocyte-bound C2 19 0 05 1
C3d during the SK infusion both for patients who received SK C3 17 -0 05 NT NT
treatment and for the control patients who did not receive SK C4 10 0 05 0 NT
treatment. It is clear that those patients with the highest levels of
SK antibodies had the strongest signs ofcomplement activation, * Difference between the baseline sample and the sample taken just
i.e. substantial increases in both free and erythrocyte-bound after the SK infusion. Changes from baseline levels never exceeded these
C3d. On the other hand, C3 did not change significantly during values at any time points, except that a rise in C3 was commonly
the SK infusion. Figure 2 shows the changes in C3, free C3d and detected at day 7.
erythrocyte-bound C3d during and after the SK infusion in t SK, Patients receiving SK treatment; C, patients not receiving SK
samples from selected patients: the three patients with the treatment. NT, Not tested.
highest baseline levels of antibodies to SK, the two patients with
the lowest baseline levels, and two control patients. Figure 2a patients, but erythrocyte-bound C3d only in one. The two
shows that C3 did not change significantly during and after the patients with no measurable antibodies to SK showed little or
SK infusion, with no value below the normal range (0 50-0 95 g/ no signs ofcomplement activation in their circulation, as did the
1). A rise was sometimes seen at day 7 at the same time as SK two control patients not receiving SK treatment, even though
antibody levels increased dramatically (see Fig. 1). It is clear that they had intermediate baseline levels of antibodies to SK (Table
patients with high levels of antibodies who received SK 1).
treatment had obvious signs of complement activation in their
circulation reflected in rise of both free C3d and erythrocyte- Erythrocyte-bound CR1 and C4d and circulating IgG-IC
bound C3d (Fig. 2b, c). The upper limit ofnormal for free C3d is Erythrocyte-bound CRI and IgG-IC levels did not change
50 AU and 94 MFCN for erythrocyte-C3d. At the end of SK following the SK treatment (data not shown), and baseline
infusion the three patients with high SK antibodies had values levels were in accordance with those seen for normal individuals.
well above these normal ranges (patient 1, 370 AU and 157 In patients with high baseline levels of SK antibodies a minimal
MFCN; patient 2, 470 AU and 112 MFCN; patient 3, 390 AU rise was detected for erythrocyte-bound C4d. This was much
and 114 MFCN for free C3d and erythrocyte-C3d respectively). less obvious than the rise in erythrocyte-bound C3d and never
Free C3d had reached baseline levels on day 7 in all three exceeded 10%.
1.6 500 -a160 (
.4 a (b)a 140
1.2 *. 400 120
0300 ~~~~~~~~Z100< 0.8 ------. 80
~0.6 ~200 2 6000.4 oo .. 400.2 20
0t1h 12 h 7 01h 12 h 7 O 1h 12h7
patients; three patients with the highest baseline SK antibody levels are indicated by unbroken lines, two patients with the lowest
baseline levels by broken lines and two control patients not receiving SK treatment by dotted lines. 0, SKpt 1;O*, SKpt 2; 0, SKpt 3;U*,
SKpt 12; A, SKpt 13; *, Cpt 1; O., Cpt 2. MFCN, Median fluorescence.
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DISCUSSION
Several investigators have established elegant experimental
models to investigate in vivo IC formation and clearance and
complement activation in humans [15-17]. These models are
rather laborious and invasive, however, and demand special
reagents like radiolabelled antigens or infusion of specific
foreign antibodies. The aim of this study was to establish a more
simple model to explore some of the same problems, but mainly
to evaluate the clinical value and sensitivity of new laboratory
assays.
As recorded, many of our myocardial infarction patients
had serum antibodies to SK before receiving SK treatment [12].
The antibody levels dropped markedly during SK infusion, and
this drop is best explained by formation of IC between the
infused SK and serum SK antibodies and subsequent clearance
of the complexes by the reticulo-endothelial system. This
decrease in SK antibody levels could also be explained by the
presence of free SK in the post-infusion samples interfering with
the SK antibodies in the ELISA assay by competition. This was
controlled for by mixing pre-infusion serum from a patient with
high level ofSK antibodies and I -h serum from a patient with no
SK antibodies. No drop in SK antibody level was obseved,
although SK antibody detection could easily be inhibited by
adding a large amount ofexogenous SK to a pre-infusion serum
containing SK antibodies (data not shown).
It was rather surprising that we could not detect any increase
in circulating IC just after the SK infusion. This cannot be
explained by lack of sensitivity of our ELISA IC assay, as IC
formed in vitro by mixing SK and serum containing SK
antibodies could easily be detected. The most plausible explana-
tion is that the amount of IC formed was well within the
clearance capacity of the immune system, and was therefore
removed very rapidly from the circulation. This is supported by
the fact that none of the SK-treated patients suffered any serum
sickness-like symptoms. Although the pharmacological half-life
in individuals without SK antibodies is about 80 min, it has been
reported that the presence ofcirculating antibodies shortens this
time dramatically [18]. Others have shown that when preformed
IC are infused intravenously, the majority is eliminated from the
circulation within minutes [15-17].
Of the seven different parameters evaluated in this study,
only measurement of free C3d and erythrocyte-bound C3d
showed significant changes during and after the SK infusion.
Demonstrable increases in free C3d occurred only in those
patients with high or moderate baseline SK antibody levels, and
increases in erythrocyte-bound C3d only occurred in the three
patients with the highest baseline SK antibody levels. The
increase in these two parameters correlated with the baseline
levels ofSK antibodies and therefore the probable amount of IC
formed. This shows that both assays are sensitive and to some
extent quantitative indicators of IC formation and subsequent
complement activation. After IC formation stopped and IC had
been cleared from the circulation, free C3d dropped rapidly and
was already near to or at baseline levels after 12 h. In contrast,
erythrocyte-bound C3d normalized more slowly, with only one
of the three patients reaching baseline levels on day 7. Like
changes in free C3d and erythrocyte-bound C3d, decreases in
serum C3 correlated somewhat with the baseline levels of SK
antibodies, but the drop was always very unimpressive, and
serum C3 never fell below the normal range. It is therefore
obvious that a decrease in serum C3 is a much less sensitive
indicator of complement activation than the increase in both
free C3d and erythrocyte-bound C3d. Moreover, the rise in
serum C3 on day 7 suggests that in a clinical situation, where
complement activation is only moderate, the expected drop in
serum C3 due to its consumption could easily be masked by an
acute-phase increase in C3 production.
It is well documented that in active immune complex
diseases, erythrocyte CR1 decreases in number and erythrocyte-
bound C3d and C4d increase [ 19]. We did not see any changes in
erythrocyte CR1 or erythrocyte-bound C4d, probably due to
the small and transient IC load in our model.
Our conclusion is that patients receiving SK infusion make a
simple but useful model to evaluate methods to monitor in vivo
IC formation and complement activation. Measurements offree
C3d by ELISA and erythrocyte-bound C3d by flow cytometry
are sensitive, reliable and quantitative methods to detect in vivo
complement activation, and are much more sensitive than a
drop in serum C3, which can also be influenced by increased C3
production as a result of an acute-phase response. Free C3d is
more sensitive, but both methods can detect and quantify even
subclinical short-lasting complement activation. The differences
between free C3d and erythrocyte-bound C3d is not only
sensitivity, as free C3d normalizes rapidly after complement
activation stops, but erythrocyte-bound C3d stays raised at least
for a few days. Thus the former parameter only reflects ongoing
complement activation, but a rise in erythrocyte-bound C3d can
also reflect a recent although terminated complement acti-
vation.
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